Enable JavaScript to visit this website.

Now FDA Approved

Introducing TALZENNA®, a once-daily oral treatment.

TALZENNA is a prescription medicine used to treat adults with:

  • a certain type of breast cancer (human epidermal growth factor receptor 2 [HER2]-negative), and
  • an abnormal inherited BRCA gene, and
  • whose cancer has spread to other parts of the body (locally advanced or metastatic).

Your healthcare provider will perform a test to make sure that TALZENNA is right for you.
It is not known if TALZENNA is safe and effective in children.

View the PRESS RELEASE about the FDA approval of TALZENNA

Learn More

Pfizer Oncology TogetherTM

Making Your Support Needs A Priority. Together.

Co-Pay Assistance

Eligible, commercially insured patients may pay as little as $0 per month for TALZENNA.* There are no income requirements, forms, or faxing to enroll. To find out more, call 1-877-744-56751-877-744-5675 to speak with a specialist.

*Limits, terms, and conditions apply. This card is not valid for prescriptions that are eligible to be reimbursed, in whole or in part, by Medicaid, Medicare, Tricare or other federal or state healthcare programs and the Government Health Insurance Plan available in Puerto Rico. Patients may receive up to $25,000 in savings annually. The offer will be accepted only at participating pharmacies. This offer is not health insurance. No membership fees apply. For any questions, please call 1-877-744-56751-877-744-5675, visit PfizerOncologyTogether.com/terms, or write: Pfizer Oncology Together Co-Pay Savings Program, 2250 Perimeter Park Drive, Suite 300, Morrisville, NC 27560.

You are now leaving TALZENNA.com.

Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of the sites that are not owned and operated by Pfizer.

The information provided in this website is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.